BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• 

  Cancer

  GSK Touts 42% Survival Benefit for Blenrep in Multiple Myeloma, Strengthening Bid for Market Return

  The overall survival edge over J&J’s Darzalex will help GSK strengthen its case as it plots the market comeback of Blenrep, which was pulled after a failed confirmatory study.

  December 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Neurodegenerative disease

  UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy

  In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified Huntington’s Disease Rating Scale, and neurofilament light chain levels to support the accelerated approval of its gene therapy AMT-130.

  December 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline

  Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to developing therapies for fibrosis, oncology and autoimmune diseases.

  December 10, 2024

   · 

  2 min read

   · 

  Angela Gabriel
• 

  CAR-T

  Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti

  Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.

  December 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  Lilly’s Strong Phase III Survival Data for Jaypirca Clouded by Deaths

  According to Jake Van Naarden, president of Lilly Oncology, the excess deaths could be due to the high rate of crossover in BRUIN CLL-321.

  December 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Theradaptive Obtains FDA IDE Approval to Study OsteoAdapt™ SP in Additional Spinal Fusion Indications

  December 10, 2024

   · 

  3 min read
• Press Releases

  BostonGene Unveils Transformative Breast Cancer Research at 2024 San Antonio Breast Cancer Symposium, Showcasing Precision Tools for Tailored Treatment Approaches

  December 10, 2024

   · 

  3 min read
• Press Releases

  Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Oral CDK2 Inhibitor at San Antonio Breast Cancer Symposium

  December 10, 2024

   · 

  3 min read
• Press Releases

  Huonslab Announces Enrollment and Administration of First Patient in Phase 1 Pivotal Study for Hydizyme™ (rHuPH20)

  December 10, 2024

   · 

  2 min read
• Press Releases

  Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies

  December 10, 2024

   · 

  15 min read